News | November 05, 2012

Paradise Renal Denervation System Shows 100% Response Rate at One-Year

Clinical trial of ultrasound-based renal denervation system shows it reduces resistant hypertension

Paradise System ReCor Medical Hypertension Therapies Renal Denervation

November 5, 2012 — ReCor Medical reported one-year follow-up data on patients who have been treated via renal denervation for their resistant hypertension with the company’s Paradise System — the only CE-marked system for renal denervation that is based on ultrasound, not radiofrequency energy. The data were presented at Transcatheter Cardiovascular Therapeutics (TCT) 2012 by Peter Fitzgerald, M.D., Ph.D., associate professor of medicine (cardiology), associate professor of electrical engineering (by courtesy) and co-director of the Center for Research in Cardiovascular Interventions at Stanford University School of Medicine. Additionally, Fitzgerald serves as director of Core Cardiovascular Analysis Lab at Stanford.

The data showed that 100 percent (15/15) patients have responded favorably to their Paradise treatment. Three of these responders are now out to one-year follow-up. The accepted industry standard for a ‘responder’ is defined as >10 mm Hg systolic office blood pressure reduction. The scientific literature demonstrates that only a 5 mm Hg reduction in blood pressure results in a 14 percent decrease in stroke, a 9 percent decrease in heart disease and a 7 percent decrease in mortality.

“These preliminary clinical results, with all of the Paradise patients responding to treatment, are very compelling and dramatically underscore a significant competitive advantage for ReCor’s ultrasound-based Paradise?system compared to radiofrequency-based standard of care for treating resistant hypertension patients,” said Mano Iyer, CEO of ReCor Medical. “The benefit of our ultrasound approach is that Paradise is designed to simultaneously penetrate much deeper into the tissue, up to 10 mm, and heat circumferentially, to target all of the renal nerves in one location. Our unique approach is in stark contrast to radiofrequency, which is limited with its depth of penetration to just a few millimeters, as well as its inability to heat circumferentially in any given location. Data presented at TCT 2012 concluded that renal nerves are actually much further at depth than previously thought, and run circumferentially around the renal arteries, which underscores the Paradise ultrasound advantage.”

Paradise is approved for sale in Europe. It is not approved for sale or investigational use in the United States.

For more information:

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init